Gelatine methacrylamide-based hydrogels: An alternative three-dimensional cancer cell culture system

作者: Elke Kaemmerer , Ferry P.W. Melchels , Boris M. Holzapfel , Tobias Meckel , Dietmar W. Hutmacher

DOI: 10.1016/J.ACTBIO.2014.02.035

关键词:

摘要: Modern cancer research requires physiological, three-dimensional (3-D) cell culture platforms, wherein the physical and chemical characteristics of extracellular matrix (ECM) can be modified. In this study, gelatine methacrylamide (GelMA)-based hydrogels were characterized established as in vitro vivo spheroid-based models for ovarian cancer, reflecting advanced disease stage patients, with accumulation multicellular spheroids tumour fluid (ascites). Polymer concentration (2.5-7% w/v) strongly influenced hydrogel stiffness (0.5±0.2kPa to 9.0±1.8kPa) but had little effect on solute diffusion. The diffusion coefficient 70kDa fluorescein isothiocyanate (FITC)-labelled dextran 7% GelMA-based was only 2.3 times slower compared water. Hydrogels medium (5% w/v GelMA) (3.4kPa) allowed spheroid formation high proliferation metabolic rates. inhibition metalloproteinases consequently ECM degradability reduced incorporation components laminin-411 hyaluronic acid further stimulated growth within hydrogels. feasibility pre-cultured carriers an animal model proven led development metastasis. These tumours sensitive treatment anti-cancer drug paclitaxel, not integrin antagonist ATN-161. While paclitaxel its combination ATN-161 resulted a response 33-37.8%, alone no peritoneal spread. semi-synthetic biomaterial GelMA combines relevant natural cues tunable properties, providing alternative, bioengineered 3-D systems.

参考文章(71)
Daniela Loessner, Kathryn S. Stok, Matthias P. Lutolf, Dietmar W. Hutmacher, Judith A. Clements, Simone C. Rizzi, Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials. ,vol. 31, pp. 8494- 8506 ,(2010) , 10.1016/J.BIOMATERIALS.2010.07.064
Genee Y Lee, Paraic A Kenny, Eva H Lee, Mina J Bissell, Three-dimensional culture models of normal and malignant breast epithelial cells Nature Methods. ,vol. 4, pp. 359- 365 ,(2007) , 10.1038/NMETH1015
Hilary A. Kenny, Ernst Lengyel, MMP-2 functions as an early response protein in ovarian cancer metastasis Cell Cycle. ,vol. 8, pp. 683- 688 ,(2009) , 10.4161/CC.8.5.7703
Linda G. Griffith, Melody A. Swartz, Capturing complex 3D tissue physiology in vitro Nature Reviews Molecular Cell Biology. ,vol. 7, pp. 211- 224 ,(2006) , 10.1038/NRM1858
Veli-Matti Kosma, Maarit A. Anttila, Seppo V. Saarikoski, Raija H. Tammi, Markku I. Tammi, Kari J. Syrjänen, High Levels of Stromal Hyaluronan Predict Poor Disease Outcome in Epithelial Ovarian Cancer Cancer Research. ,vol. 60, pp. 150- 155 ,(2000)
Franziska Hirschhaeuser, Heike Menne, Claudia Dittfeld, Jonathan West, Wolfgang Mueller-Klieser, Leoni A. Kunz-Schughart, Multicellular tumor spheroids: an underestimated tool is catching up again Journal of Biotechnology. ,vol. 148, pp. 3- 15 ,(2010) , 10.1016/J.JBIOTEC.2010.01.012
Wouter Schuurman, Peter A. Levett, Michiel W. Pot, Paul René van Weeren, Wouter J. A. Dhert, Dietmar W. Hutmacher, Ferry P. W. Melchels, Travis J. Klein, Jos Malda, Gelatin-methacrylamide hydrogels as potential biomaterials for fabrication of tissue-engineered cartilage constructs. Macromolecular Bioscience. ,vol. 13, pp. 551- 561 ,(2013) , 10.1002/MABI.201200471
Karen D. Cowden Dahl, Jaime Symowicz, Yan Ning, Elisa Gutierrez, David A. Fishman, Brian P. Adley, M. Sharon Stack, Laurie G. Hudson, Matrix Metalloproteinase 9 Is a Mediator of Epidermal Growth Factor–Dependent E-Cadherin Loss in Ovarian Carcinoma Cells Cancer Research. ,vol. 68, pp. 4606- 4613 ,(2008) , 10.1158/0008-5472.CAN-07-5046
Dieter Prechtel, Elisabeth Konik, Stefan Rutke, Ernst Lengyel, Barbara Schmalfeldt, Kathrin Härting, Manfred Schmitt, Kerstin Späthe, Walther Kuhn, Ursula Berger, Rafael Fridman, Increased Expression of Matrix Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type Plasminogen Activator Is Associated with Progression from Benign to Advanced Ovarian Cancer Clinical Cancer Research. ,vol. 7, pp. 2396- 2404 ,(2001)